

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TATA Health International Holdings Limited

TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

(1) DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS AND DESPATCH OF THE 2024 ANNUAL REPORT; (2) QUARTERLY UPDATE ON RESUMPTION PROGRESS; AND (3) CONTINUED SUSPENSION OF TRADING

Reference is made to the announcements made by the board (the “**Board**”) of directors (the “**Directors**”) of TATA Health International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 2 April 2024, 18 April 2024, 5 June 2024, 27 June 2024, 28 June 2024, 31 July 2024, 30 September 2024, 4 October 2024 and 3 January 2025 (collectively the “**Announcements**”) pursuant to, among other things, Rules 13.09(2)(a) and 13.24A of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those defined in the Announcements.

DELAY IN PUBLICATION OF THE ANNUAL RESULTS AND DESPATCH OF THE ANNUAL REPORT FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024

Pursuant to Rules 13.49(1) and 13.46(2)(a) of the Listing Rules, the Company is required to publish an announcement in relation to the preliminary financial results of the Group for the year ended 31 December 2024 (the “**2024 Annual Results**”) no later than three months after the end of the financial year (i.e. on or before 31 March 2025) and to send the annual report for the same period (the “**2024 Annual Report**”) to the shareholders of the Company (the “**Shareholders**”) no later than 30 April 2025.

As at the date of this announcement, the auditor of the Company is in the process of conducting the relevant audit procedures for the audit of the 2023 Annual Results. As the publication of the 2023 Annual Results and the 2024 Interim Results are still pending, it is expected that the 2024 Annual Results will not be published by 31 March 2025 and the 2024 Annual Report will not be despatched to the Shareholders by 30 April 2025, respectively, as required under the Listing Rules.

The Board acknowledges that the delay in publication of the 2024 Annual Results and in despatch of the 2024 Annual Report would constitute non-compliance with Rule 13.49(1) and Rule 13.46(2)(a) of the Listing Rules, respectively.

The Company will publish further announcement(s) as and when appropriate to inform the Shareholders of the expected date of the publication of the 2024 Annual Results and the despatch of the 2024 Annual Report.

UPDATE ON BUSINESS OPERATIONS

The Board would also like to inform Shareholders and potential investors of the latest development of the Group's business operations and the progress of actions recently taken by the Company in connection with fulfilling the Resumption Guidance.

Reference is made to the quarterly update announcement of the Company of 3 January 2025. The Company would like to provide the updates in relation to (i) the bankruptcy proceedings of Shangying Medical; (ii) the recovery of the Loan; and (iii) the proposed disposal of SY Health, as follows:

- (1) **Bankruptcy proceedings of Shangying Medical** — As Shangying Medical is currently insolvent, it is highly unlikely that its debts could be paid off by the auction of its assets. Hence, after completing the auction and/or disposal of Shangying Medical's assets, the Administrator may apply to the relevant PRC Court to declare Shangying Medical bankrupt. Due to the uncertainty regarding the time required for the auction and/or disposal of Shangying Medical's assets, the Administrator is currently unable to make a concrete assessment of the expected completion time of the bankruptcy proceedings.
- (2) **Recovery of the Loan by SY Health** — As previously announced, SY Health has, on 12 December 2024, issued a termination notice to Century Health in accordance with the Loan Deed and has engaged a legal adviser to handle the recovery of the Loan. Despite subsequent reminders and demand letters being sent to Century Health and to the personal guarantors, namely Mr. Wenfei Yang and Mr. Hao Ding, the Loan (together with all other amounts owing thereunder including accrued and unpaid interest) is still outstanding as at the date of this announcement. Having considered, among others, (i) the practical challenges in the recovery of the Loan, given that the assets of SY Health and the personal guarantors (if any) are primarily located in

Australia; and (ii) the current stagnant debt recovery status, the Company is considering to make a substantial impairment relating to the Loan in the financial statements for the year ended 31 December 2024.

- (3) **Proposed disposal of SY Health** — The Company is also considering a potential disposal of SY Health while retaining the Loan within the Group due to (i) the long-term loss-making position of SY Health over the years; and (ii) the repeated unmet requests for the provision of relevant financial information by SY Health. Further announcement(s) will be made by the Company in this regard where appropriate.

Save as disclosed above, notwithstanding the suspension of trading in the Company's shares, up to the date of this announcement, the Group is carrying on its business operations as usual in all material respects and will continue to assess and monitor its financial position and business operations. Nonetheless, given the financial difficulty currently faced by the Company, despite every effort has been made by the management of the Company to work closely with all relevant parties towards the publication of the outstanding financial results and the resumption of trading in the Company's shares, the shortage of funds has inevitably impacted and delayed the relevant progress.

UPDATE ON PROGRESS OF RESUMPTION

Below is the Resumption Guidance of the Stock Exchange and the Company's resumption plan with details of actions that the Company has taken or intends to take as well as the expected timeframe in fulfilling the Resumption Guidance to resume trading in its shares:

Resumption Guidance	Update on resumption progress and the expected timeline
(i) publish all outstanding financial results required under the Listing Rules and address any audit modifications	<p>As at the date of this announcement, the auditor of the Company is in the progress of conducting the relevant audit procedures for the audit of 2023 Annual Results.</p> <p>Based on information currently available, it is expected that the 2023 Annual Results, the 2024 Interim Results and the 2024 Annual Results would be published by the Company by or around 30 April, 31 May and 30 June 2025, respectively.</p>

- | | |
|---|---|
| (ii) demonstrate the Company's compliance with Rule 13.24 | <p>Since the suspension of trading in the Company's shares on 2 April 2024 and up to the date of this announcement, save as disclosed above, the business operations of the Group have operated as usual in all material respects.</p> <p>The Company's compliance with Rule 13.24 of the Listing Rules would be assessed with the publication of the outstanding financial results.</p> |
| (iii) inform the market of all material information for the Shareholders and potential investors to appraise the Company's position | <p>Since the suspension of trading in the Company's shares on 2 April 2024, the Company has kept the Shareholders and potential investors informed of all material information in relation to, among others, the Resumption Guidance and other relevant updates and progresses by way of announcements.</p> <p>The Company will continue to keep the Shareholders and potential investors informed of any relevant material developments by making further announcement(s) as and when appropriate in accordance with the requirements under the Listing Rules.</p> |

The expected timeline for publication of the outstanding financial results is indicative only and may or may not be updated depending on, among others, any additional audit procedures.

The Company will publish further announcement(s) of the status and development of the Company as and when appropriate, as well as announce quarterly updates on its development of the resumption status in accordance with the Listing Rules.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 2 April 2024 and will remain suspended pending the fulfilment of the Resumption Guidance. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

The Shareholders and potential investors of the Company are advised to invest cautiously and to be aware of the investment risks.

By Order of the Board
TATA Health International Holdings Limited

Hong Kong, 31 March 2025

As at the date of this announcement, the Board comprises three non-executive Directors, namely, Mr. Lin Zheming, Mr. Chu Chun Ho, Dominic and Ms. Jiang Juqi; and three independent non-executive Directors, namely, Mr. Wang Jian, Mr. Tao Chi Keung and Mr. Cai Tsz Yeung.